SIXFOLD BIOSCIENCE LTD

Their core work

Sixfold Bioscience is a London-based biotech SME specializing in RNA and DNA nanotechnology for therapeutic delivery. They engineer nanoparticles — including RNA origami structures and protein corona modifications — to deliver nucleic acid therapies (mRNA, gene silencing agents) into cells more effectively. Their work sits at the intersection of synthetic biology, directed evolution, and AI-guided design, with applications in cancer treatment, Huntington's disease, and broader gene therapy. They are a delivery technology company: they don't develop the drugs themselves, but build the vehicles that get them where they need to go.

What they specialise in

How they've shifted over time

Sixfold's H2020 participation spans only 2020–2021 start dates, so the evolution window is narrow. Their earliest projects (mRNA NanoDeli, NanoRNA_PC) focused purely on the biophysics of RNA nanoparticle delivery — engineering the particles themselves. Their most recent project (DESTINATION, 2021) marks a clear shift toward AI-enabled delivery design and larger-scale ambition, with by far their biggest budget. The trajectory moves from lab-scale nanoparticle engineering toward computationally guided, programmable delivery platforms.

Sixfold is moving from wet-lab RNA nanotechnology toward AI-augmented delivery design — expect them to seek partners with computational biology and machine learning capabilities.

How they like to work

Sixfold strongly prefers to lead: they coordinated 3 of their 4 projects, indicating confidence in their technology direction and willingness to take on project management. With 20 unique partners across 9 countries from just 4 projects, they build broad, diverse consortia rather than relying on repeat partners. This suggests an organization actively expanding its network and open to new collaborations, making them approachable for first-time partners.

Despite being a small company with only 4 projects, Sixfold has built a surprisingly wide network of 20 unique partners across 9 countries. This breadth suggests strong European connections for a young biotech SME, likely spanning universities, research institutes, and pharma-adjacent companies.

What sets them apart

Sixfold occupies a rare niche as an SME that owns delivery technology for nucleic acid therapeutics — most delivery work happens inside large pharma or university labs, not in agile startups. Their combination of RNA origami structural design with AI-guided optimization is distinctive; few organizations bridge wet-lab nanotechnology and computational delivery design at this scale. For consortium builders, they offer a focused, coordinator-experienced SME that brings proprietary delivery platform technology rather than just research capacity.

Highlights from their portfolio

• DESTINATION
  Their largest project (EUR 886K) and most ambitious — combines AI with RNA nanotechnology for programmable cellular delivery, signaling the company's strategic direction.
• NanoRNA_PC
  Addresses the underexplored protein corona problem in RNA nanoparticle delivery — a critical bottleneck that determines whether nanoparticles reach their target or get cleared by the immune system.
• OLIGOMED
  Their only participant role, in a large MSCA training network running until 2026 — connects them to the broader European oligonucleotide therapeutics research community.